BaseLaunch is a top ranked biotech accelerator
At BaseLaunch, we incubate and accelerate therapeutic ventures. BaseLaunch was named one of the top ten European Accelerators and we are always on the lookout for next-generation biotech ventures to support. We help early stage companies, researchers, scientists and entrepreneurs with growing their companies that are developing cutting-edge therapeutics. We help get them to the point where they can complete a Series A financing or similar.
Since early 2018, BaseLaunch has supported nine ventures that have, in total, raised over 200 million USD in financing. Several pharma collaborations have been initiated and one company has been sold. As of December 2019, we have added another four companies to our portfolio. Furthermore, BaseLaunch has been contributing to the development of six more ventures in the Basel Area (ABBA therapeutics, Alibion, Avicenna Oncology, Captor Therapeutics, FoRx Therapeutics, Sunregen.)
Because of our success in the first phase of the program, in 2020 the second phase has now been launched and the available funding increased to up to $500,000 per company. Partners for the second phase include: Roche, BB Pureos Bioventures, Roivant Sciences, Bridge Bioventures, CSL Behring, Johnson & Johnson.
BaseLaunch offers financing but also much more, including access to our partners, global biopharma and investors; assistance with the company and team build-out; free access to labs & related infrastructure where needed. We ensure our ventures become deeply embedded in what is arguably Europe’s strongest biotech ecosystem. The Basel Area touts academia and life science industry, a great network of talent and a hotbed for innovation.
We invite you to visit our site where you can read our success stories, learn more about the great ecosystem, and apply to participate.
BaseLaunch is managed and operated by Basel Area Business & Innovation, the innovation and investment promotion agency for the Basel Area.
At BaseLaunch, we incubate and accelerate therapeutic ventures. BaseLaunch was named one of the top ten European Accelerators and we are always on the lookout for next-generation biotech ventures to support. We help early stage companies, researchers, scientists and entrepreneurs with growing their companies that are developing cutting-edge therapeutics. We help get them to the point where they can complete a Series A financing or similar.
Since early 2018, BaseLaunch has supported nine ventures that have, in total, raised over 200 million USD in financing. Several pharma collaborations have been initiated and one company has been sold. As of December 2019, we have added another four companies to our portfolio. Furthermore, BaseLaunch has been contributing to the development of six more ventures in the Basel Area (ABBA therapeutics, Alibion, Avicenna Oncology, Captor Therapeutics, FoRx Therapeutics, Sunregen.)
Because of our success in the first phase of the program, in 2020 the second phase has now been launched and the available funding increased to up to $500,000 per company. Partners for the second phase include: Roche, BB Pureos Bioventures, Roivant Sciences, Bridge Bioventures, CSL Behring, Johnson & Johnson.
BaseLaunch offers financing but also much more, including access to our partners, global biopharma and investors; assistance with the company and team build-out; free access to labs & related infrastructure where needed. We ensure our ventures become deeply embedded in what is arguably Europe’s strongest biotech ecosystem. The Basel Area touts academia and life science industry, a great network of talent and a hotbed for innovation.
We invite you to visit our site where you can read our success stories, learn more about the great ecosystem, and apply to participate.
BaseLaunch is managed and operated by Basel Area Business & Innovation, the innovation and investment promotion agency for the Basel Area.
Location: Switzerland, Basel-Country, Allschwil
Employees: 1-10
Founded date: 2017
Investment Type: Accelerator
Investment Stage: Pre-Seed; Seed; Series A
Portfolio 1
| Date | Name | Website | Total Raised | Location |
| 20.02.2026 | Umlaut.bio | umlaut.bio | $3.51M | Germany |
Mentions in press and media 42
| Date | Title | Description |
| 24.03.2026 | Umlaut.bio Secures €3 Million, Pioneers Novel Cancer and Autoimmune Therapies | Umlaut.bio secured €3 million in pre-seed funding. The biotech firm targets cancer and inflammatory diseases. It pioneers first-in-biology small molecules. These molecules inhibit tRNA modification synthesis. This novel mechanism prevents w... |
| 23.03.2026 | Umlaut.bio extends pre-seed round to EUR 3 million | Umlaut.bio is a pioneering biotech company focused on developing first-in-biology therapies targeting cancer and inflammatory diseases. Small molecules will be developed to inhibit key steps in tRNA modification synthesis, thereby preventi... |
| 20.02.2026 | Cancer and immunology player Umlaut.bio adds funding to reach ~€3 million pre-Seed total | Umlaut.bio, a German/Swiss oncology/immunology BioTech company developing tRNA-modifying small molecules, announced the extension of its pre-Seed financing to ~€3 million through the support of BaseLaunch. This addition not only helps to ac... |
| 17.07.2024 | Practical guidelines for startups: from start to scaling | Building a startup is another school of experience where startups acquire different skills to help them build thriving businesses. Different channels such as podcasts allow experts to share their knowledge and practical tips. In this lates... |
| 19.06.2024 | NXI Therapeutics extends pre-seed financing to CHF 3.5 million | NXI Therapeutics, a spin-off from the Biozentrum at University of Basel, is committed to creating tomorrow’s disruptive immunotherapies through modulation of coronin 1 in immune cells. Coronin 1 depletion in preclinical models allows long-... |
| 03.05.2022 | Engimmune Therapeutics raises CHF 15.5 million in seed financing | |
| 20.10.2021 | Global pharma companies grow interest in Swiss Lifesciences | |
| 05.10.2021 | Акселераторы, о которых должны знать MedTech-стартапы | Акселераторы, о которых должны знать MedTech-стартапы |
| 05.10.2021 | Must-know accelerators for MedTech-startups | Must-know accelerators for MedTech-startups |
| 05.10.2021 | Акселераторы, о которых должны знать MedTech-стартапы | Акселераторы, о которых должны знать MedTech-стартапы |
Show more